Clinical trials: Kidney Failure,Chronic
Kidney Disease, Chronic
An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Patients With Chronic Kidney Disease Not On Dialysis
This observational, prospective, multicenter study will describe the mean dose of Mircera (methoxy polyethylene glycol-epoetin beta) and the hemoglobin levels in patients with chronic kidney disease.
- Trial name
- NCT01318512
- Where
- Czechia
- Volunteers
- 340 people
- Sponsor
- Hoffmann-La Roche
End Stage Renal Disease
Conventional Hemodialysis vs. Short Daily Hemodialysis (6 Days / Week) and Mechanisms of Blood Pressure Control
More than 80% of patients with end stage renal disease have hypertension; 70% of whom are poorly controlled using conventional Hemodialysis therapy.
- Trial name
- NCT00759967
- Testing
- Microneurography, Bioimpedance testing
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- Ottawa Hospital Research Institute
Anemia, End Stage Renal Disease
16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis
The purpose of this study is to evaluate the hemoglobin response (efficacy), safety, and tolerability of orally administered AKB-6548 in participants with end stage renal disease undergoing chronic hemodialysis.
- Trial name
- NCT02260193
- Testing
- AKB-6548
- Where
- 16 sites in United States
- Volunteers
- 94 people
- Sponsor
- Akebia Therapeutics
Chronic Kidney Diseases, Hyperkalemia
Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet.
The purpose of this proof-of-concept controlled-feeding study is to determine whether patiromer (Veltassa®, Relypsa, Inc., Redwood City, CA) can be used to maintain normal serum potassium concentrations in chronic kidney disease…
- Trial name
- NCT03183778
- Testing
- Patiromer, Research Diet Menu
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- NYU Langone Health
Hyperphosphatemia, Kidney Failure
A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis
This is up to a 58 week study comparing ferric citrate to active control for 52 weeks in ESRD dialysis patients, and subsequently comparing ferric citrate to placebo for 4 weeks.
- Trial name
- NCT01191255
- Where
- 56 sites in United States, Israel and 1 more
- Volunteers
- 441 people
- Sponsor
- Keryx Biopharmaceuticals
Kidney Failure, Chronic, Hemodialysis Complication
The Pristine Post-Market Study
This is a prospective, multi-center, single-arm study designed to assess the safety and performance of the Pristine™ Long-Term Hemodialysis Catheter.
- Conditions
- Kidney Failure, Chronic, Hemodialysis Complication, Hemodialysis Catheter Infection, Hemodialysis Access Failure
- Trial name
- NCT05228132
- Testing
- Pristine™ Long-Term Hemodialysis Catheter
- Where
- 6 sites in United States
- Volunteers
- 142 people
- Sponsor
- C. R. Bard
Kidney Failure, Chronic, Cardiovascular Disease
Hydroxychloroquine in Cardiovascular Disease in Patients With Chronic Kidney Disease: A Proof of Concept Study
Presence of multiple traditional and nontraditional risk factors of atherosclerosis and cardiovascular disease (CVD) including inflammation in patients with chronic kidney disease (CKD) contribute to high CVD morbidity and…
- Conditions
- Kidney Failure, Chronic, Cardiovascular Disease, Arteriosclerosis
- Trial name
- NCT01537315
- Testing
- Hydroxychloroquine
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Arkansas
Renal Failure Chronic, Anemia
Predictors of Response to Iron and Erythropoietin Stimulating Agents
The purpose of the study is to identify predictors of treatment response. This involves collected baseline clinical parameters and bloods for biochemical parameters prior to administering the study treatment.
- Trial name
- PRIME (NCT03658876)
- Testing
- Iron Sucrose Solution for Injection, Epoetin Beta
- Volunteers
- 197 people
- Sponsor
- Imperial College London
End Stage Renal Disease
An Effectiveness-Implementation Trial of SPIRIT in ESRD
Despite advances in dialysis, only 50% of dialysis patients are alive 3 years after the onset of end-stage renal disease (ESRD).
- Trial name
- NCT03138564
- Testing
- SPIRIT, Comparison Condition
- Where
- 39 sites in United States
- Volunteers
- 852 people
- Sponsor
- Emory University
Chronic Kidney Disease
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
The primary objective of this study was to demonstrate whether, in addition to standard of care, finerenone is superior to placebo in delaying the progression of kidney disease, as measured by the composite endpoint of time to…
- Trial name
- FIDELIO-DKD (NCT02540993)
- Testing
- Finerenone (BAY94-8862)
- Where
- 978 sites in United States, Argentina and 46 more
- Volunteers
- 5,734 people
- Sponsor
- Bayer
Chronic Kidney Diseases
Survey on Anemia Therapy in Participants With Chronic Kidney Disease (CKD) Not on Dialysis
This study is a prospective, non-interventional, cross-sectional multicenter survey. The aim is to better understand the current therapy pattern for anemia in CKD treated with erythropoiesis-stimulating agents (ESAs) and not…
- Trial name
- NCT02238067
- Testing
- ESA, Satisfaction Survey Questionnaire
- Where
- 7 sites in Israel
- Volunteers
- 196 people
- Sponsor
- Hoffmann-La Roche
End Stage Renal Disease
DIVINE: Dialysis Infection and Vitamin D In New England
Infection is the second-leading cause of death in individuals requiring dialysis treatment for kidney failure. New research suggests the high risk of infection may be due in part to low levels of vitamin D, which are extremely…
- Trial name
- NCT00892099
- Testing
- Ergocalciferol
- Where
- 3 sites in United States
- Volunteers
- 105 people
- Sponsor
- Massachusetts General Hospital
Chronic Kidney Disease
Vascular Reactivity in Chronic Kidney Disease (CKD) Patients Receiving Paricalcitol Versus Placebo
This research is studying how Vitamin D may affect blood vessels reaction to stress and blood levels of substances that may increase blockages in the blood vessels in chronic kidney disease (CKD) patients.
- Trial name
- NCT00915876
- Testing
- Paricalcitol
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Amy Barton Pai
Chronic Kidney Disease (CKD), End-stage Renal Disease (ESRD)
Impact of Vitamin D Therapies on Chronic Kidney Disease
This investigation will consist of a prospective study utilizing two separate populations of patients with 25(OH)D deficiency, one population with chronic kidney disease (CKD) and one with normal renal function.
- Trial name
- NCT01222234
- Testing
- Cholecalciferol - CKD, Calcitriol - CKD, Cholecalciferol - non-CKD
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- University of Kansas Medical Center
End Stage Renal Disease
A Representational Intervention to Promote Preparation for End-of-life Decision Making
The proposed randomized controlled trial will test the SPIRIT (Sharing the Patient's Illness Representations to Increase Trust) intervention designed to improve discussions about end-of-life care between patients and their…
- Trial name
- SPIRIT (NCT01259011)
- Testing
- the SPIRIT intervention
- Where
- United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Cancer
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
RATIONALE: Antithymocyte globulin, clofarabine, and rituximab may stop the patient's immune system from rejecting the donor's stem cells when they do not exactly match the patient's blood.
- Trial name
- NCT00617929
- Testing
- anti-thymocyte globulin, rituximab, clofarabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Hyperphosphatemia, Chronic Kidney Disease
Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects
The primary objective is to assess the effects of colestilan on the pharmacokinetic profile of candesartan cilexetil when administered at the same time as, 1 hour before, and 3 hours after the first daily dose of colestilan…
- Trial name
- NCT01976572
- Testing
- colestilan, candesartan
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
End Stage Renal Disease, Hyperphosphatemia
A Study of Ferric Citrate to Improve Inflammation and Lipid Levels
The risk of cardiovascular mortality in patients with end stage renal disease on hemodialysis is 10-100 times higher than the normal population.
- Conditions
- End Stage Renal Disease, Hyperphosphatemia, Chronic Inflammation
- Trial name
- NCT02661295
- Testing
- Ferric Citrate
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Winthrop University Hospital
End-Stage Renal Disease (ESRD), End-Stage Kidney Disease (ESKD)
Single Dose Study of MK-2060 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Older Japanese Participants on Dialysis (MK-2060-012)
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of MK-2060 after a single dose intravenous (IV) administration in Japanese older participants with end stage renal…
- Conditions
- End-Stage Renal Disease (ESRD), End-Stage Kidney Disease (ESKD), Kidney Failure, Chronic
- Trial name
- NCT05769595
- Testing
- MK-2060
- Where
- 12 sites in Japan
- Volunteers
- 17 people
- Sponsor
- Merck Sharp & Dohme LLC
Renal Failure Chronic Requiring Hemodialysis, Chronic Renal Insufficiency
VectorFlow Tunneled Dialysis Catheter (TDC) Versus Palindrome TDC
Randomized two-arm study examining 90 day primary patency of two FDA-approved tunneled dialysis catheters.
- Trial name
- TDC (NCT02685995)
- Testing
- VectorFlow TDC, Palindrome TDC
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- University of Pennsylvania